Targeting Anaplastic Lymphoma Kinase in Lung Cancer
Alice T Shaw, Benjamin Solomon
Clinical Cancer Research | AMER ASSOC CANCER RESEARCH | Published : 2011
Several decades of cancer research have revealed a pivotal role for tyrosine kinases as key regulators of signaling pathways, controlling cell growth and differentiation. Deregulation of tyrosine kinase-mediated signaling occurs frequently in cancer and is believed to drive the initiation and progression of disease. Chromosomal rearrangements involving the tyrosine kinase anaplastic lymphoma kinase (ALK) occur in a variety of human malignancies including non-small cell lung cancer (NSCLC), anaplastic large cell lymphomas, and inflammatory myofibroblastic tumors. The aberrant activation of ALK signaling leads to "oncogene addiction" and marked sensitivity to ALK inhibitors such as crizotinib ..View full abstract
A.T. Shaw, commercial research support, Novartis, AstraZeneca; consultant, Pfizer, Millennium Pharmaceuticals. B. Solomon, commercial research support, consultant, Pfizer.